Table 3.
Baseline characteristics by treatment group of participants that developed new-onset type 2 diabetes.
| Colchicine (n = 34) | Placebo (n = 49) | p-valuea | |
|---|---|---|---|
| Demographics | |||
| Age, mean (SD), years | 60.9 (8.6) | 62.6 (9.8) | 0.40 |
| Female, No. (%) | 3 (8.8) | 10 (20.4) | 0.15 |
| Clinical characteristics | |||
| Hypertension, No. (%) | 18 (52.9) | 22 (44.9) | 0.47 |
| Current smoker, No. (%) | 10 (30.3) | 11 (22.4) | 0.42 |
| Creatinine clearance <60 ml/min/1.73 m2, No. (%) | 3 (8.8) | 3 (6.1) | 0.64 |
| Prior acute coronary syndrome, No. (%) | 30 (88.2) | 43 (87.8) | 0.95 |
| Prior coronary revascularization, No. (%) | 31 (91.2) | 41 (83.7) | 0.32 |
| Coronary artery bypass grafting, No. (%) | 2 (5.9) | 7 (14.3) | 0.23 |
| Percutaneous coronary intervention, No. (%) | 30 (88.2) | 36 (73.5) | 0.10 |
| History of atrial fibrillation, No. (%) | 2 (5.9) | 5 (10.2) | 0.49 |
| Medication at enrollment | |||
| Single antiplatelet therapy, No. (%) | 20 (58.8) | 26 (53.1) | 0.60 |
| Dual antiplatelet therapy, No. (%) | 13 (38.2) | 18 (36.7) | 0.89 |
| Anticoagulant, No. (%) | 1 (2.9) | 7 (14.3) | 0.09 |
| No antiplatelet agent or anticoagulant, No. (%) | 0 (0) | 0 (0) | — |
| Statin, No. (%) | 33 (97.1) | 49 (100) | 0.23 |
| Renin angiotensin inhibitor, No. (%) | 27 (79.4) | 37 (75.5) | 0.68 |
| Beta-blocker, No. (%) | 24 (70.6) | 35 (71.4) | 0.93 |
a
p-values for comparison between groups were calculated using the chi-square test for proportions and independent sample t-test for means.